Clinical Trials Logo

Filter by:
NCT ID: NCT03921684 Recruiting - Rectal Cancer Clinical Trials

Trial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer Patients

Start date: April 2019
Phase: Phase 2
Study type: Interventional

This is a phase II, prospective, open label, one-center study for evaluation of the addition of nivolumab to the chemotherapy phase of the neoadjuvant treatment for locally advanced rectal cancer patients. Subjects must have received no prior treatment for rectal cancer (chemotherapy, radiotherapy or surgery) and no prior treatment with checkpoint inhibitors. Eligible subjects will receive chemoradiation for a period of 5 weeks, 6 cycles of chemo-immunotherapy (mFOLFOX6 + nivolumab) for a period of 12 weeks, once every 2 weeks, and will undergo surgery after 4 weeks.

NCT ID: NCT03920774 Recruiting - Clinical trials for Hereditary Sensory and Autonomic Neuropathies

The Natural History of Familial Dysautonomia

Start date: February 22, 2017
Phase:
Study type: Observational

The study will collect clinical information from patients with FD and allow them to give blood to help develop biological markers of the disease to aid diagnosis and treatment. This is a non-invasive, non-interventional, observation study that poses only minimal risk for participants. The study will document the clinical features of patients with FD overtime by storing their routine clinical test results in a central database. The study will involve collaborators at other specialist clinics around the world who follow/evaluate patients with FD annually. Providing blood for future use is optional.

NCT ID: NCT03919461 Recruiting - Clinical trials for Colorectal Neoplasms

Colorectal Metastasis Prevention International Trial 2

COMPIT-2
Start date: February 28, 2019
Phase: Phase 2
Study type: Interventional

The short perioperative period (days to weeks around surgery) is characterized by stress-inflammatory responses, including catecholamines (CAs, e.g., adrenaline) and prostaglandins (PGs, e.g., prostaglandin-E2) release, and induce deleterious pro-metastatic effects. Animal studies implicated excess perioperative release of CAs and PGs in facilitating cancer progression by affecting the malignant tissue, its local environment, and anti-metastatic immune functions. Congruently, animal studies conducted by the investigators indicate that combined use of the beta-adrenergic blocker, propranolol, and the prostaglandins inhibitor, etodolac - but neither drug separately - efficiently prevented post-operative metastatic development. Two recently conducted clinical trials, conducted by the investigators, in three medical centers in Israel, recruiting breast (n=38) and colorectal (n=34) cancer patients, assessing the safety and short-term efficacy of perioperative propranolol and etodolac treatment. Drugs were well tolerated, without severe adverse events. Importantly, molecular/biological analyses of the excised primary tumor indicated that drug treatment caused promising anti-metastatic transformations, as well as improvements in immune and inflammatory indices. These included (i) decreased tumor cell capacity to migrate, (ii) reduced pro-metastatic capacity of the malignant tissue, and (iii) improvement in immune infiltrating into the tumor (Paper published in Clinical Cancer Research, 2017). Herein, the investigators propose to conduct a double-blind placebo-controlled two-arm Phase II clinical trial in 200 colorectal cancer patients undergoing curative surgery in Israel. A perioperative 20-day drug treatment will be initiated 5 days before surgery. Primary outcomes will include (i) 3-year disease-free-survival (DFS), and 5-year overall survival (OS); and (ii) biological markers in blood samples, and in the excised tumor tissue. Secondary outcomes will include safety indices and psychological measures of depression, anxiety, distress, and fatigue

NCT ID: NCT03917641 Not yet recruiting - Surgery Clinical Trials

Effectiveness of Khat on Eyelid Wound Healing After Oculoplastic Surgery - a Prospective Study.

Start date: July 1, 2019
Phase: N/A
Study type: Interventional

The post operative routine after Oculoplastic Surgery includes usage of cold compressions for symptomatic relief and decreasing of the edema and local hematomas in the first few days after the surgery. Khat (Catha edulis) is a plant that is used mainly for chewing and has a known stimulating effect, some patients report major improvement after including these leaves in the compressions they use after surgery. Khat contains the chemical ingredients Cathine and Cathinone, which are amphetamine-like alkaloids and probably the main contributors for its active effects. Our main goal is to use compressions that include the Khat leaves and check their effect on reducing the edema and hematomas after oculoplastic surgery.

NCT ID: NCT03917615 Recruiting - Clinical trials for Pelvic Floor Muscle Weakness

Pelvic Floor Muscle Contraction Among Physiotherapy Students Before and After "Women Health" Course

Start date: April 8, 2019
Phase: N/A
Study type: Interventional

The study aim is to evaluate the ability to correctly contract pelvic floor muscle among physiotherapy students before and after "women health" course. Pelvic floor muscle contraction will be evaluated via transabdominal ultrasound.

NCT ID: NCT03917381 Not yet recruiting - Clinical trials for Non-small Cell Lung Cancer

GEN1046 Safety Trial in Patients With Malignant Solid Tumors

Start date: May 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the trial is to evaluate the safety of GEN1046 in patients with malignant solid tumors

NCT ID: NCT03915964 Not yet recruiting - Clinical trials for Rheumatoid Arthritis

A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis

RA-BRIDGE
Start date: April 22, 2019
Phase: Phase 4
Study type: Interventional

This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis.

NCT ID: NCT03914911 Recruiting - Breast Cancer Clinical Trials

In Vivo Smart Biopsy Device Protocol In Radiology

Start date: March 14, 2019
Phase: N/A
Study type: Interventional

This study is designed to demonstrate the feasibility of use of the Smart Biopsy Device in real clinical settings.

NCT ID: NCT03912558 Recruiting - BPH Clinical Trials

Pilot Study to Assess the Safety and Efficacy of Butterfly Medical Prostatic Retraction Device in Benign Prostatic Hyperplasia (BPH) Patients.

Start date: October 23, 2018
Phase: N/A
Study type: Interventional

This study evaluates the safety and efficacy of use of the Butterfly Medical's prostatic retraction device in Benign Prostatic Hyperplasia (BPH) Patients. The study follows patients implanted with the Butterfly device for up to 1 year after implantation. Evaluations include recording of safety events and BPH related symptoms by Uroflowmetry tests and International Prostate Symptom Score (IPSS) questionnaires. The study also assess sexual quality of life after implantation of the Butterfly device.

NCT ID: NCT03908021 Not yet recruiting - Clinical trials for Type1 Diabetes Mellitus

The Salivary Microbiome in Children With Type 1 Diabetes Mellitus

Start date: April 2019
Phase:
Study type: Observational [Patient Registry]

Aims: To profile the oral microbiome of children with type 1 diabetes mellitus, and to compare it to heathy children while taking into account other aspects of the oral environment. Research: exploring the differences between oral microflora of children with type 1 diabetes mellitus and control healthy children using salivary microbiome. The investigators will furthermore intend to analyze the differences of salivary flow rate, pH, glucose, calcium, inorganic phosphate and urea between the two groups.